Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAG regimen versus decitabine in elderly acute myeloid leukemia patients unfit for standard chemotherapy
ChiCTR-IIR-16008962Phase 3Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2016
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of homoharringtonine, cytarabine, filgrastim and decitabine in acute myeloid leukemia (AML) (2 arms), sponsored by Ruijin Hospital. Primary endpoints: Overall survival and Disease-free survival. Planned start Sep 2016; status: not yet recruiting.
02
Drugs
homoharringtoninecytarabinefilgrastimdecitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-IIR-16008962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-16008962.